Loading…
Patent Eligibility Restoration Act of 2024
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (17)
Referred to the House Committee on the Judiciary.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Copyright/Patent/Trademark
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: Not reported · Firm income: $110,000
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office
2026 · second_quarter · Copyright/Patent/Trademark
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826).
Client expense: Not reported · Firm income: $110,000
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office
2025 · first_quarter · Copyright/Patent/Trademark
General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies H.R. 9474 Patent Restoration Act (PERA) of 2024 S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Copyright/Patent/Trademark
General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Copyright/Patent/Trademark
General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act S. 1095. The Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 2276/H.R. 3269 Eliminating Thickets to Increase Competition Act (Ethics Act)
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
H.R. 1, the One Big, Beautiful Bill Act H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act S 106 / HR 539 - Chiropractic Medicare Coverage Modernization Act PAMA reform HR 2483, Support for Patients and Communities Reauth Act HR 2484, Seniors access to Critical medications act Reducing Hereditary Cancer Act S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S 1830 - the Right to Treat Act S 1811 - Prohibits Graduate medical schools from receiving Federal assistance if DEI policies are in place S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine S 2066, Medicare transaction Fraud prevention act LCD legislation S 1866 - National Breast and Cervical Cancer Early Detection Program S 1882 - to expand research and training on reproductive health conditions HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 HR 3164 - Ensuring Community Access to Pharmacy Services Act (ECAPS) S 2800 - Pharmacy and Medically Underserved Areas Enhancement Act S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to tariffs Issues related to public health
Client expense: $124,816 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Copyright/Patent/Trademark
General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140, H.R. 9474 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S.1367, H.R. 2794, No Fakes Act
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
H.R. 1, the One Big, Beautiful Bill Act H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Seniors timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act S 106 / HR 539 - Chiropractic Medicare Coverage Modernization Act PAMA reform HR 2483, Support for Patients and Communities Reauth Act HR 2484, Seniors access to Critical medications act Reducing Hereditary Cancer Act S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S 1830 - the Right to Treat Act S 1811 - Prohibits Graduate medical schools from receiving Federal assistance if DEI policies are in place S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine S 2066, Medicare transaction Fraud prevention act LCD legislation S 1866 - National Breast and Cervical Cancer Early Detection Program S 1882 - to expand research and training on reproductive health conditions HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act
Client expense: $149,447 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Copyright/Patent/Trademark
General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies H.R. 9474 Patent Restoration Act (PERA) of 2024 S. 527, Prescription Pricing for the People Act of 2025 S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S. 1097, Interagency Patent Coordination and Improvement Act of 2025
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Health Issues
HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act
Client expense: $217,588 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Copyright/Patent/Trademark
Issues related to patent quality, Inter Partes Review, and the Patent Trial and Appeal Board (PTAB). Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370 (in the 118th Congress); Patent Eligibility Restoration Act, S. 2140 and HR 9474 (in the 118th Congress); RESTORE Patent Rights Act of 2024, S. 4840 and HR 9221 (in the 118th Congress).
Client expense: Not reported · Firm income: Not reported
2024 · third_quarter · Copyright/Patent/Trademark
Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patent Eligibility Restoration Act. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.4878: The Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.8134: Restoring Americas Leadership In Innovation Act of 2024. H.R.9221/S.4840: Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024.
Client expense: $530,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
Patent abuse issues. S. 150 Affordable Prescriptions for Patients Act of 2023. S. 79 Interagency Patent Coordination Act. S. 2780 Medication Affordability and Patent Integrity Act S. 142 Preserve Access to Affordable Generics and Biosimilars Act Joint USPTO-FDA Collaboration Initiatives. S. 2140/H.R.9474 Patent Eligibility Restoration Act of 2023 S. 2220/H.R.4370 PREVAIL Act S. 3583 A bill to address patent thickets. H.R. 6986 To address patent thickets. S.5573 A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
H.R. 4370 and S. 2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act A bill to amend title 35, United States Code, to invest in inventors in the United States, maintain the United States as the leading innovation economy in the world, and protect the property rights of the inventors that grow the economy of the United States, and for other purposes (ALL). H.R. 9474 and S. 2140: Patent Eligibility Restoration Act A bill to amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes (ALL). H.R. 9455 and S. 4713: Inventor Diversity for Economic Advancement (IDEA) Act A bill to amend chapter 11 of title 35, United States Code, to require the voluntary collection of demographic information for patent inventors, and for other purposes (ALL).
Client expense: $70,000 · Firm income: Not reported
2024 · fourth_quarter · Health Issues
Issues related to Therapies for Rare Diseases - Reauthorization of Pediatric Rare PRV, Modifications to IRA, and Access to Home Infusions; H.R. 9474 - Continuing Appropriations and Extension Act, 2025. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Client expense: $130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
Issues related to patent reform legislation; H.R.9474 - Patent Eligibility Restoration Act (PERA) of 2024; S. 2140 - Patent Eligibility Restoration (PERA) Act of 2023; H.R. 4370/S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act.
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
General advocacy in support of pro-IP/innovation policies S. 2220, H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. 2140 - Patent Eligibility Restoration Act (PERA) Opposition to misuse of March-in provisions under the Bayh-Dole Act Opposition to FTC proposal to limit non-compete agreements ITC - IP-related issues S. 2934, H.R. 8684 - SHOP Safe Act Injunctive relief for patent rights holders S. 4840, H.R. 9221 - The RESTORE Patent Rights ACT of 2024 S.4713 - The IDEA Act S.2780 - The Medication Affordability and Patent Integrity Act Proposed Changes to Standard Essential Patent (SEPs) Policies H.R. 9474 Patent Restoration Act (PERA) of 2024
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
Patent abuse issues. S. 150/H.R. 9070 - Affordable Prescriptions for Patients Act of 2023. S. 79 - Interagency Patent Coordination Act. S. 2780 - Medication Affordability and Patent Integrity Act. S. 142 - Preserve Access to Affordable Generics and Biosimilars Act. Joint USPTO-FDA Collaboration Initiatives. H.R. 9474/S. 2140 - Patent Eligibility Restoration Act of 2023. H.R. 4370/S. 2220 - PREVAIL Act. S. 3583 - A bill to address patent thickets. H.R. 6986 - A bill to address patent thickets. H.R. 10545 - American Relief Act
Client expense: Not reported · Firm income: $80,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patient Eligibility Restoration Act of 2023. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act of 2024. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.5573: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products.
Client expense: $800,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act
Client expense: $126,566 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
S. 2220/H.R. 4370, PREVAIL Act S. 2140/H.R. 9474, Patent Eligibility Restoration Act of 2023
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
General discussions regarding patent-related issues, including march-in rights, WTO TRIPS waivers S. 2140/H.R. 9474 -- Patent Eligibility Restoration Act -- sections related to treatment of patent applications and their eligible status at the USPTO H.R 4370/S. 2220 -- PREVAIL Act -- related to reforms of the PTAB process at USPTO S. 4820/H.R. 9221 -- RESTORE Patent Rights Act -- related to reforms of patent law regarding injunctions against patent infringers H.R. 5475 -- Prohibiting Adversarial Patents Act -- To amend title 35, United State Code, to require the Director of the United States Patent and Trademark Office to require disclosures in patent applications regarding ties to the Peoples Republic of China and other foreign adversaries NIST Request for Information (Docket No. 230831-0207) Regarding the Draft Interagency Guidance Framework for Consideringthe Exercise of March-in Rights S. 4713 -- Inventor Diversity for Economic Advancement Act (IDEA) -- related to voluntary reporting of demographic information of patentees H.R. 8134 -- Restoring American Leadership in Innovation Act -- To promote the leadership of the United States in global innovation by establishing a robust patent system that restores and protects the right of inventors to own and enforce private property rights in inventions and discoveries, and for other purposes -- all sections
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
S.4875/H.R. 9551, the NO FAKES Act of 2023 S. 2780, the Medication Affordability and Patent Integrity Act H.R. 9455/ S. the IDEA Act H.R. 9211/S. 4840, the RESTORE Patent Rights Act of 2024 S. 5160, Sharing of information with respect to suspected violations of intellectual property rights. H.R. 8134, the Restoring America's Leadership in Innovation Act of 2024 (RALIA) H.R. 8132, Balancing Incentives Act of 2024 H.R. 7913, Generative AI Copyright Disclosure Act of 2024 H.R. 6684/S. 3569, Improving Efficiency to Increase Competition Act H.R. 5475, Prohibiting Adversarial Patents Act of 2023 H.R. 6436, Stopping Pharmas Ripoffs and Drug Savings For All Act S, 2934, the SHOP SAFE Act of 2023 H.R. 5475, Prohibiting Adversarial Patents Act of 2023 S. 2566, the American IP Defense and Enforcement Advancement Act H.R. 9474/S. 2140, Patent Eligibility Restoration Act of 2023 S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act H.R. 1707, the SMART Act S. 1128, Ensuring Access to Generic Medications Act S.835/H.R.1631, the Pro Codes Act S. 746/H.R. 1505, the No Stolen Trademarks Honored in America Act S. 574, Increasing Prescription Drug Competition Act S. 253/H.R. 791, the American Music Fairness Act of 2023 S. 153, the Fair Trade with China Enforcement Act S. 150, the Affordable Prescriptions for Patients Act S. 113 Pricing for the People Act S. 79/H.R. 1717, the Interagency Patent Coordination and Improvement Act of 2023. S. 42, Prescription Preserve Access to Affordable Generics and Biosimilars Act H.R.2594 - To control the export to the People's Republic of China of certain technology and intellectual property important to the national interest of the United States, and for other purposes. H.R. 2070 - To provide for a limitation on availability of funds for Executive Office of the President, Intellectual Property Enforcement Coordinator for fiscal year 2024 H.R. 1016, the Stop Chinas IP Theft Act H.R. 906 , the REPAIR Act H.R. 576, the Copyright Clause Restoration Act of 2023 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2024 · fourth_quarter · Copyright/Patent/Trademark
S. 2220/H.R. 4370, PREVAIL Act S. 2140/H.R. 9474, Patent Eligibility Restoration Act of 2023
Client expense: Not reported · Firm income: $21,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Copyright/Patent/Trademark
S.4875/H.R. 9551, the NO FAKES Act of 2023 S. 2780, the Medication Affordability and Patent Integrity Act H.R. 9455/ S. the IDEA Act H.R. 9211/S. 4840, the RESTORE Patent Rights Act of 2024 S. 5160, Sharing of information with respect to suspected violations of intellectual property rights. H.R. 8134, the Restoring America's Leadership in Innovation Act of 2024 (RALIA) H.R. 8132, Balancing Incentives Act of 2024 H.R. 7913, Generative AI Copyright Disclosure Act of 2024 H.R. 6684/S. 3569, Improving Efficiency to Increase Competition Act H.R. 5475, Prohibiting Adversarial Patents Act of 2023 H.R. 6436, Stopping Pharmas Ripoffs and Drug Savings For All Act S, 2934, the SHOP SAFE Act of 2023 H.R. 5475, Prohibiting Adversarial Patents Act of 2023 S. 2566, the American IP Defense and Enforcement Advancement Act H.R. 9474/S. 2140, Patent Eligibility Restoration Act of 2023 S. 2220/H.R. 4370, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act H.R. 1707, the SMART Act S. 1128, Ensuring Access to Generic Medications Act S.835/H.R.1631, the Pro Codes Act S. 746/H.R. 1505, the No Stolen Trademarks Honored in America Act S. 574, Increasing Prescription Drug Competition Act S. 253/H.R. 791, the American Music Fairness Act of 2023 S. 153, the Fair Trade with China Enforcement Act S. 150, the Affordable Prescriptions for Patients Act S. 113 Pricing for the People Act S. 79/H.R. 1717, the Interagency Patent Coordination and Improvement Act of 2023. S. 42, Prescription Preserve Access to Affordable Generics and Biosimilars Act H.R.2594 - To control the export to the People's Republic of China of certain technology and intellectual property important to the national interest of the United States, and for other purposes. H.R. 2070 - To provide for a limitation on availability of funds for Executive Office of the President, Intellectual Property Enforcement Coordinator for fiscal year 2024 H.R. 1016, the Stop Chinas IP Theft Act H.R. 906 , the REPAIR Act H.R. 576, the Copyright Clause Restoration Act of 2023 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2024 · third_quarter · Copyright/Patent/Trademark
S. 2140: Patent Eligibility Restoration Act of 2023: Provisions regarding Section 2(b )(1 )(B)(i) and Section 2(b )(1 )(B)(ii), which exclude most inventions implemented in software from patent eligibility as these inventions are not patent ineligible in other countries. H.R. 9474: Patent Eligibility Restoration Action of 2024; all provisions of the bill. S. 2220/H.R. 4370: Promoting and Respecting Economically Vital American Innovation Leadership Act of 2023 (PREVAIL ACT): Seeking an amendment to balance incentives within the Patent Trial and Appeal Board (PTAB). H.R. 8132: Balancing Incentives Act of 2024: all provisions of the bill. H.R. 8134: Restoring America's Leadership in Innovation Act of 2024: all provisions of the bill.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Copyright/Patent/Trademark
H.R. 4370 and S. 2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act A bill to amend title 35, United States Code, to invest in inventors in the United States, maintain the United States as the leading innovation economy in the world, and protect the property rights of the inventors that grow the economy of the United States, and for other purposes (ALL). H.R. 9474 and S. 2140: Patent Eligibility Restoration Act A bill to amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes (ALL). H.R. 9455 and S. 4713: Inventor Diversity for Economic Advancement (IDEA) Act A bill to amend chapter 11 of title 35, United States Code, to require the voluntary collection of demographic information for patent inventors, and for other purposes (ALL).
Client expense: $80,000 · Firm income: Not reported
2024 · third_quarter · Copyright/Patent/Trademark
Patent abuse issues. S. 150/H.R. 9070 - Affordable Prescriptions for Patients Act of 2023. S. 79 - Interagency Patent Coordination Act. S. 2780 - Medication Affordability and Patent Integrity Act. S. 142 - Preserve Access to Affordable Generics and Biosimilars Act. Joint USPTO-FDA Collaboration Initiatives. H.R. 9474/S. 2140 - Patent Eligibility Restoration Act of 2023. H.R. 4370/S. 2220 - PREVAIL Act. S. 3583 - A bill to address patent thickets. H.R. 6986 - A bill to address patent thickets.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
2024 · third_quarter · Copyright/Patent/Trademark
Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patent Eligibility Restoration Act. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.4878: The Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.8134: Restoring Americas Leadership In Innovation Act of 2024. H.R.9221/S.4840: Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024.
Client expense: $530,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act
Client expense: $193,594 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Copyright/Patent/Trademark
Patent reform, Patent Trial and Appeal Board reform, assertion of patent exclusivity rights, H.R. 8134 (Restoring Americas Leadership in Innovation Act), S. 4840/H.R. 9221 (RESTORE Patent Rights Act), S. 2140/H.R. 9474 (Patent Eligibility Restoration Act), S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership Act), H.R. 3535 (Advancing Americas Interest Act)
Client expense: Not reported · Firm income: Not reported
S. 2220/H.R. 4370, PREVAIL Act S. 2140/H.R. 9474, Patent Eligibility Restoration Act of 2023
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Copyright/Patent/Trademark
Issues relating to patent policy including Inter Partes Review and institution decisions, patent quality, communication between patent examiners and the Patent Trial and Appeal Board (PTAB), PTAB generally, and patent eligibility; Patent Eligibility Restoration Act of 2023 (S. 2140 and HR 9474); Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (S. 2220 and HR 4370); RESTORE Patent Rights Act of 2024 (S. 4840 and HR 9221).
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
Issues related to Therapies for Rare Diseases - Reauthorization of Pediatric Rare PRV, Modifications to IRA, and Access to Home Infusions; H.R. 9474 - Continuing Appropriations and Extension Act, 2025.
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Copyright/Patent/Trademark
S. 2220/H.R. 4370, PREVAIL Act S. 2140/H.R. 9474, Patent Eligibility Restoration Act of 2023
Client expense: Not reported · Firm income: $21,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Copyright/Patent/Trademark
General discussions regarding patent-related issues, including march-in rights, WTO TRIPS waivers S. 2140/H.R. 9474 -- Patent Eligibility Restoration Act -- sections related to treatment of patent applications and their eligible status at the USPTO H.R 4370/S. 2220 -- PREVAIL Act -- related to reforms of the PTAB process at USPTO S. 4820/H.R. 9221 -- RESTORE Patent Rights Act -- related to reforms of patent law H.R. 5475 -- Prohibiting Adversarial Patents Act -- To amend title 35, United State Code, to require the Director of the United States Patent and Trademark Office to require disclosures in patent applications regarding ties to the Peoples Republic of China and other foreign adversaries NIST Request for Information (Docket No. 230831-0207) Regarding the Draft Interagency Guidance Framework for Consideringthe Exercise of March-in Rights S. 4713 -- Inventor Diversity for Economic Advancement Act (IDEA) -- related to voluntary reporting of demographic information of patentees Clauses in grants issued by ARPA-H regarding cost for inventions created using such funding H.R. 8134 -- Restoring American Leadership in Innovation Act -- To promote the leadership of the United States in global innovation by establishing a robust patent system that restores and protects the right of inventors to own and enforce private property rights in inventions and discoveries, and for other purposes -- all sections
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE